Clinical Trial

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Study acronym: EASE SBS 5
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.
Protocol Amendment History 2 changes
notable Trial sites expanded: 23 -> 31 locations 2026-08-13
notable Trial sites expanded: 19 -> 23 locations 2026-04-21
Trial Details
NCT Number NCT07197944
Lead Sponsor Zealand Pharma
Conditions Short Bowel Syndrome
Enrollment 90 participants
Start Date 2026-02-11
Primary Completion 2028-10-23 (estimated)
Study Completion 2032-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-12